Answers are grounded in this paper and cite their sources.
Overall results were improved by neither the administration of G-CSF nor by cycle therapy; however, the latter was easier to perform. Compared with study AML-BFM 93, therapy intensification with HAM in standard-risk patients did not result in improved prognosis. Future treatment designs have to balance intensification of treatment with higher toxicity, improve supportive care, and to consider alternative treatment strategies.
No takes yet. Share an insight, caveat, or question.
Creutzig et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: